Condition: Friedreich Ataxia · Sponsor: Design Therapeutics, Inc.
The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.
This description comes directly from the study's public registry record.
Varlli Scott · +613 8341 6228 · varlli.scott@mcri.edu.au
Always discuss trial participation with your own doctor first.
| Scientia Clinical Research Ltd | Sydney, New South Wales, Australia | Recruiting |
| Doherty Clinical Trials | East Melbourne, Victoria, Australia | Recruiting |
| Nucleus Network | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06874010